Literature DB >> 21478730

Lupus erythematosus-like reaction in imiquimod-treated skin: a report of 2 cases.

May P Chan1, Mary Jane Zimarowski.   

Abstract

Imiquimod (Aldara) is a topical immune response modifier effective against a variety of cutaneous tumors. Post therapy histologic reaction patterns have not been well characterized. Here, we present 2 patients treated with imiquimod, whose biopsies showed interface dermatitis of the epidermis and the adnexae with prominent periadnexal and perivascular lymphocytic inflammation. Without the clinical history, these histologic findings may be misinterpreted as lupus erythematosus. This report describes a new finding in imiquimod-treated skin and supports the diversity of reaction patterns that may be seen in association with imiquimod treatment.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21478730     DOI: 10.1097/DAD.0b013e3181f2bf9e

Source DB:  PubMed          Journal:  Am J Dermatopathol        ISSN: 0193-1091            Impact factor:   1.533


  4 in total

1.  A model of skin inflammation in humans leads to a rapid and reproducible increase in the interferon response signature: a potential translational model for drug development.

Authors:  Marion C Dickson; Valerie J Ludbrook; Hayley C Perry; Paul A Wilson; Sam J Garthside; Michael H Binks
Journal:  Inflamm Res       Date:  2015-01-18       Impact factor: 4.575

2.  Immunogenicity in humans of a transdermal multipeptide melanoma vaccine administered with or without a TLR7 agonist.

Authors:  Max O Meneveau; Gina R Petroni; Elise P Salerno; Kevin T Lynch; Mark Smolkin; Elizabeth Woodson; Kimberly A Chianese-Bullock; Walter C Olson; Donna Deacon; James W Patterson; William W Grosh; Craig L Slingluff
Journal:  J Immunother Cancer       Date:  2021-05       Impact factor: 13.751

3.  Using topical imiquimod for the management of positive in situ margins after melanoma resection.

Authors:  Amrita S Pandit; Erik J Geiger; Stephan Ariyan; Deepak Narayan; Jennifer Nam Choi
Journal:  Cancer Med       Date:  2015-01-26       Impact factor: 4.452

4.  Accelerated model of lupus autoimmunity and vasculopathy driven by toll-like receptor 7/9 imbalance.

Authors:  Yudong Liu; Nickie L Seto; Carmelo Carmona-Rivera; Mariana J Kaplan
Journal:  Lupus Sci Med       Date:  2018-05-14
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.